tipranavir

(redirected from Aptivus)
Also found in: Medical.
Related to Aptivus: Invirase, Fuzeon, Lexiva, Agenerase
Translations

tipranavir

n tipranavir m
References in periodicals archive ?
Everyone who entered the trial had a viral load above 1000 copies when the study began, and no one had taken Kaletra, Prezista, Aptivus (tipranavir), or Fuzeon (enfuvirtide) before.
rate /based on local currency (Euro) DRUGS APPROVED/LAUNCHED Drug Indication Cymbalta generalized anxiety disorder (EU) Aptivus oral solution for treatment-experienced HIV pediatric patients; suppression of HIV in highly treatment experienced patients (U.
The company produces and sells prescription and over-the-counter remedies for a number of therapeutic areas--Spiriva and Atrovent for respiratory ailments, Micardis for high blood pressure, Flomax for enlarged prostate, and HIV/AIDS products Aptivus and Viramune, among others.
McCallister coordinated the design, conduct, and analysis of more than 20 Phase I, II, and III tipranavir development trials, culminating in the FDA and EMEA approval of APTIVUS for the treatment of HIV infection in treatment-experienced patients.
Reports of fatal and nonfatal intracranial hemorrhage among HIV-1 infected patients taking Aptivus (tipranavir) in combination antiretroviral therapy have prompted the manufacturer to issue new safety information.
Reports of fatal and nonfatal intracraial hemorrhage among HIV-1 infected patients taking Aptivus (tipranavir) in combination antiretroviral therapy have prompted the manufacturer to issue new safety information.
The lower price could well be in the company's financial interest, by allowing first-line use if the drug proves suitable--especially important now that its rival Aptivus (tipranavir) does not seem to be working well as a first-line treatment, with a clinical trial stopped because of performance that appeared slightly inferior to a good standard treatment based on Kaletra.
Aptivus (tipranavir), a protease inhibitor in capsule form, is manufactured by Boehringer Ingelheim Pharmaceuticals Inc.
Boehringer Ingelheim: strong reliance on Viramune and Aptivus as key setback for future growth in HIV
Resistant virus may gain the upper hand after a switch to Isentress but may remain under control with continued Kaletra therapy, or continued therapy with another PI boosted by Norvir (ritonavir), such as Aptivus (tipranavir), Invirase (saquinavir), Lexiva (fosamprenavir).
In the letter, Chiang explains how high drug costs for key AIDS drugs--such as Abbott's Kaletra, BI's Aptivus, BMS' Reyataz and Genentech's Invirase and Fuzeon--are contributing to the current ADAP crisis:
5 (intermediate 0 (low penetration) penetration) Nucleoside or nucleotide reverse transcriptase inhibitors Retrovir (zidovudine) Emtriva Videx (didanosine) (emtricitabine) Ziagen (abacavir) Epivir (lamivudine) Viread (tenofovir) Zerit (stavudine) Nonnucleoside reverse transcriptase inhibitors Viramune (nevirapine) Sustiva (efavirenz) Intelence (etravirine) * Protease inhibitors Crixivan (indinavir) Reyataz (atazanavir) Aptivus (tipranavir) + (+ RTV) RTV Kaletra (lopinavir + Reyataz + RTV Invirase (saquinavir) RTV) + RTV Agenerase[dagger] Prezista (darunavir) + Norvir (ritonavir) (amprenavir) + RTV RTV Viracept (nelfinavir) Entry inhibitors Selzentry Fuzeon (enfuvirtide) (maraviroc) * Integrase inhibitors Isentress (raltegravir) * RTV = ritonavir (Norvir).